Mineralys’s lorundrostat has demonstrated its potential to reduce blood pressure in patients with hypertension again, as the aldosterone synthase inhibitor has achieved a third clinical win in recent months giving close fight to AstraZeneca’s baxdrostat.
Key Takeaways
- Lorundrostat met key efficacy and safety endpoints in the Phase II Explore-CKD trial, showing blood pressure and kidney benefits.
The biotech firm has announced positive topline data from its Phase II Explore-CKD trial evaluating the safety and efficacy of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?